Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu girentuximab plus cabozantinib and nivolumab in treatment-naive advanced ccRCC
NCT05663710Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2023
- Primary completion
- Oct 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of 177-Lu-DOTA-cG250 in clear cell renal cell carcinoma (ccRCC) (3 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events (NCI CTCAE v5.0) and Complete Response Rate by RECIST 1.1. Started Jun 2023; status: recruiting.
02
Drugs
177-Lu-DOTA-cG250
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05663710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663710.